Circulating Tumor DNA Levels Predict Treatment Outcomes for Patients with Gastroesophageal Cancer Treated with a Novel Immunotherapy Combination
Johns Hopkins MedicineMonitoring levels of DNA shed by tumors and circulating in the bloodstream could help doctors accurately assess how gastroesophageal cancers are responding to treatment, and potentially predict future prognosis, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.